Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Trifluoromethyl fluorocoxib a detects cyclooxygenase-2 expression in inflammatory tissues and human tumor xenografts.

Uddin MJ, Crews BC, Huda I, Ghebreselasie K, Daniel CK, Marnett LJ.

ACS Med Chem Lett. 2014 Jan 23;5(4):446-50. doi: 10.1021/ml400485g. eCollection 2014 Apr 10.

2.

Molecular imaging of cyclooxygenase-2 in canine transitional cell carcinomas in vitro and in vivo.

Cekanova M, Uddin MJ, Bartges JW, Callens A, Legendre AM, Rathore K, Wright L, Carter A, Marnett LJ.

Cancer Prev Res (Phila). 2013 May;6(5):466-76. doi: 10.1158/1940-6207.CAPR-12-0358. Epub 2013 Mar 26.

3.

Fluorinated COX-2 inhibitors as agents in PET imaging of inflammation and cancer.

Uddin MJ, Crews BC, Ghebreselasie K, Huda I, Kingsley PJ, Ansari MS, Tantawy MN, Reese J, Marnett LJ.

Cancer Prev Res (Phila). 2011 Oct;4(10):1536-45. doi: 10.1158/1940-6207.CAPR-11-0120. Epub 2011 Sep 7.

4.

Targeted imaging of cancer by fluorocoxib C, a near-infrared cyclooxygenase-2 probe.

Uddin MJ, Crews BC, Ghebreselasie K, Daniel CK, Kingsley PJ, Xu S, Marnett LJ.

J Biomed Opt. 2015 May;20(5):50502. doi: 10.1117/1.JBO.20.5.050502.

5.

Fluorocoxib A loaded nanoparticles enable targeted visualization of cyclooxygenase-2 in inflammation and cancer.

Uddin MJ, Werfel TA, Crews BC, Gupta MK, Kavanaugh TE, Kingsley PJ, Boyd K, Marnett LJ, Duvall CL.

Biomaterials. 2016 Jun;92:71-80. doi: 10.1016/j.biomaterials.2016.03.028. Epub 2016 Mar 21.

6.

Single-dose safety and pharmacokinetic evaluation of fluorocoxib A: pilot study of novel cyclooxygenase-2-targeted optical imaging agent in a canine model.

Cekanova M, Uddin MJ, Legendre AM, Galyon G, Bartges JW, Callens A, Martin-Jimenez T, Marnett LJ.

J Biomed Opt. 2012 Nov;17(11):116002. doi: 10.1117/1.JBO.17.11.116002.

7.

The 2'-Trifluoromethyl Analogue of Indomethacin Is a Potent and Selective COX-2 Inhibitor.

Blobaum AL, Uddin MJ, Felts AS, Crews BC, Rouzer CA, Marnett LJ.

ACS Med Chem Lett. 2013 May 9;4(5):486-490. Epub 2013 Mar 25.

8.

Design, synthesis, and structure-activity relationship studies of fluorescent inhibitors of cycloxygenase-2 as targeted optical imaging agents.

Uddin MJ, Crews BC, Ghebreselasie K, Marnett LJ.

Bioconjug Chem. 2013 Apr 17;24(4):712-23. doi: 10.1021/bc300693w. Epub 2013 Mar 28.

9.

Detection of non-melanoma skin cancer by in vivo fluorescence imaging with fluorocoxib A.

Ra H, González-González E, Uddin MJ, King BL, Lee A, Ali-Khan I, Marnett LJ, Tang JY, Contag CH.

Neoplasia. 2015 Feb;17(2):201-7. doi: 10.1016/j.neo.2014.12.009.

10.

Fluorocoxib A enables targeted detection of cyclooxygenase-2 in laser-induced choroidal neovascularization.

Uddin MJ, Moore CE, Crews BC, Daniel CK, Ghebreselasie K, McIntyre JO, Marnett LJ, Jayagopal A.

J Biomed Opt. 2016 Sep 1;21(9):90503. doi: 10.1117/1.JBO.21.9.090503.

11.

Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts.

Raut CP, Nawrocki S, Lashinger LM, Davis DW, Khanbolooki S, Xiong H, Ellis LM, McConkey DJ.

Cancer Biol Ther. 2004 Dec;3(12):1217-24. Epub 2004 Dec 9.

PMID:
15477758
12.

[I]-Celecoxib Analogues as SPECT Tracers of Cyclooxygenase-2 in Inflammation.

Uddin MJ, Crews BC, Ghebreselasie K, Tantawy MN, Marnett LJ.

ACS Med Chem Lett. 2011 Feb 10;2(2):160-164. Epub 2010 Nov 12.

13.

PET imaging of cyclooxygenase-2 (COX-2) in a pre-clinical colorectal cancer model.

Tietz O, Wuest M, Marshall A, Glubrecht D, Hamann I, Wang M, Bergman C, Way JD, Wuest F.

EJNMMI Res. 2016 Dec;6(1):37. doi: 10.1186/s13550-016-0192-9. Epub 2016 Apr 26.

14.

Salvianolic acid B inhibits growth of head and neck squamous cell carcinoma in vitro and in vivo via cyclooxygenase-2 and apoptotic pathways.

Hao Y, Xie T, Korotcov A, Zhou Y, Pang X, Shan L, Ji H, Sridhar R, Wang P, Califano J, Gu X.

Int J Cancer. 2009 May 1;124(9):2200-9. doi: 10.1002/ijc.24160.

15.

Biochemical and pharmacological profile of a tetrasubstituted furanone as a highly selective COX-2 inhibitor.

Riendeau D, Percival MD, Boyce S, Brideau C, Charleson S, Cromlish W, Ethier D, Evans J, Falgueyret JP, Ford-Hutchinson AW, Gordon R, Greig G, Gresser M, Guay J, Kargman S, Léger S, Mancini JA, O'Neill G, Ouellet M, Rodger IW, Thérien M, Wang Z, Webb JK, Wong E, Chan CC, et al.

Br J Pharmacol. 1997 May;121(1):105-17.

16.

Inhibition of cancer cell proliferation and prostaglandin E2 synthesis by Scutellaria baicalensis.

Zhang DY, Wu J, Ye F, Xue L, Jiang S, Yi J, Zhang W, Wei H, Sung M, Wang W, Li X.

Cancer Res. 2003 Jul 15;63(14):4037-43.

17.

Direct evidence for a role of cyclooxygenase 2-derived prostaglandin E2 in human head and neck xenograft tumors.

Zweifel BS, Davis TW, Ornberg RL, Masferrer JL.

Cancer Res. 2002 Nov 15;62(22):6706-11.

18.

Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects.

Mohammed SI, Dhawan D, Abraham S, Snyder PW, Waters DJ, Craig BA, Lu M, Wu L, Zheng R, Stewart J, Knapp DW.

Mol Cancer Ther. 2006 Feb;5(2):329-36.

19.

COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.

Grösch S, Tegeder I, Niederberger E, Bräutigam L, Geisslinger G.

FASEB J. 2001 Dec;15(14):2742-4. Epub 2001 Oct 15.

PMID:
11606477
20.

Supplemental Content

Support Center